These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1093 related articles for article (PubMed ID: 22930785)

  • 21. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
    Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
    Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].
    Gao Q; Zhang W; Wang N; Duan H; Zhou Y; Zhang W; Zhao D
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens].
    Dujardin F; Pagès JC; Collin C; de Calan L; Lecomte P; Guyétant S
    Ann Pathol; 2010 Aug; 30(4):252-62. PubMed ID: 20837233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
    Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
    Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating BRAF
    Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
    BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
    Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
    PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection.
    Chung YS; Kim JY; Bae JS; Song BJ; Kim JS; Jeon HM; Jeong SS; Kim EK; Park WC
    Thyroid; 2009 Mar; 19(3):241-6. PubMed ID: 19265495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
    Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
    Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors for central lymph node metastases in CN0 papillary thyroid microcarcinoma (mPTC): A retrospective analysis of 1304 cases.
    Zhang Q; Wang Z; Meng X; Duh QY; Chen G
    Asian J Surg; 2019 Apr; 42(4):571-576. PubMed ID: 30348606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic lymphadenectomy of neck level II in clinically node-positive papillary thyroid carcinoma.
    Koo BS; Seo ST; Lee GH; Kim JM; Choi EC; Lim YC
    Ann Surg Oncol; 2010 Jun; 17(6):1637-41. PubMed ID: 20146100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
    Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
    Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies.
    Zatelli MC; Trasforini G; Leoni S; Frigato G; Buratto M; Tagliati F; Rossi R; Cavazzini L; Roti E; degli Uberti EC
    Eur J Endocrinol; 2009 Sep; 161(3):467-73. PubMed ID: 19574281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
    Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.